Use of human stem cell composition in preparing medicament for treating premature ovarian failure or uterine diseases

A technology for premature ovarian failure and stem cells, which can be used in sexual diseases, drug combinations, medical raw materials derived from mammals, etc.

Inactive Publication Date: 2014-03-26
唐明淇
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Its disadvantages are: accurate dosage, long-term dependence, and need to be prescribed by a doctor
[0007] Its disadvantage is that it is invalid for premature ovarian failur

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of human stem cell composition in preparing medicament for treating premature ovarian failure or uterine diseases
  • Use of human stem cell composition in preparing medicament for treating premature ovarian failure or uterine diseases
  • Use of human stem cell composition in preparing medicament for treating premature ovarian failure or uterine diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0111] Preparation of stem cell suspensions for the treatment of premature ovarian failure or uterine diseases.

[0112] Sterile gauze dipped in 75% alcohol, wipe all items needed during the operation and the operating table. (The disinfection steps involved in this operation are all wiped with 75% alcohol sterile gauze, hereinafter referred to as disinfection)

[0113] 1. Sterilize 50mL cord blood bag containing sodium citrate, and put it into 50mL No.1 liquid bottle. Pour 50mL of No. 2 liquid into the No. 1 liquid bottle, close the cap tightly, and shake well. Put the No. 1 liquid bottle on the ultra-clean table, loosen the bottle cap and let it stand for 20-30 minutes to wait for stratification. 12 centrifuge tubes are unpacked and set aside.

[0114] 2. Take No. 3 solution, sterilize the outer wall, open the cap, take 25ml of No. 3 solution with a new pipette and put it into a 50ml new centrifuge tube, pipette a total of 3 times, and get 3 centrifuge tubes with reagent ...

Embodiment 2

[0122] Pharmacological experiment, general pharmacological experiment of umbilical cord blood stem cell suspension

[0123] 1 material

[0124] 1.1 Animals: KM mice weigh 18-22 g, half male and half male. Healthy mixed-breed domestic dogs, weighing 12-18kg, both male and female. Animals were raised in SPF-level experimental animal laboratory conditions, indoor temperature was 19-22°C, relative humidity was 40%-50%, given full-price pellet feed, free to eat and drink.

[0125] 1.2 Drug: human umbilical cord blood stem cell suspension, wherein the content of stem cells is 8×10 7 pieces / ml.

[0126] 1.3 SYS-G mouse autonomous activity frequency measuring instrument of Shanghai Xinman Company, and RM-6000 multiconductor physiological recorder of American BIOPAC Company.

[0127] 2 test method

[0128] 2.1 Effects on the psycho-nervous system

[0129] 2.1.1 Effects on the general appearance and behavior of mice: 80 mice were randomly divided into four groups, 20 in each group...

Embodiment 3

[0163] Acute Toxicity Experiment of Umbilical Cord Blood Stem Cell Suspension

[0164] 1. Materials

[0165] A. Rodent group: SD rats, aged 6-9 weeks, weighing 180-240g

[0166] 1. Experimental group: 60 rats (female to male ratio 1:1)

[0167] 2. Blank control group: 20 rats (female to male ratio 1:1)

[0168] B. Non-rodent animal group: Beagle dogs, aged 6-10 months, weighing 8-15kg.

[0169] 1. Experimental group: 30 dogs (female to male ratio 1:1)

[0170] 2. Blank control group: 10 dogs (female to male ratio 1:1)

[0171] C. Drug: human umbilical cord blood stem cell suspension, wherein the content of stem cells is 8×10 7 pieces / ml.

[0172] 2. Method

[0173] 1. Route of administration: intravenous injection

[0174] 2. Dosage (initial dose, intermediate dose, maximum dose):

[0175] Group A: a, rat 2.5ml / kg b, rat 5.0ml / kg c, rat 10.0ml / kg

[0176] Group B: a, dog 1.25ml / kg b, dog 2.5ml / kg c, dog 5.0ml / kg

[0177] 3. Observation method

[0178] 2 hours af...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Weightaaaaaaaaaa
Weightaaaaaaaaaa
Weightaaaaaaaaaa
Login to view more

Abstract

The invention discloses a use of a human stem cell composition in preparing a medicament for treating premature ovarian failure or uterine diseases. The human stem cell composition which consists of in-vitro human stem cells and normal saline is prepared into stem cell suspension with volume of 10ml-80ml; the quantity of the human stem cells contained in each part of the stem cell suspension is 1*10<8>-8*10<8>. The human stem cell composition is used for treating the premature ovarian failure or uterine diseases by intravenous injection and vascular intervention, wherein intravenous infusion is safe and reliable, strong in operability and small in side effect, and the stem cells can reach a cell damaged part by virtue of blood circulation; the blood vessel interventional therapy is small in damage compared with operative treatment, capable of avoiding various subsidiary injuries and complication possibly appearing in vascular bypass surgery, quick in effect taking, and capable of being directly acted on a diseased region to establish collateral circulation and regain blood supply.

Description

technical field [0001] The present invention relates to the use of a medicine for treating premature ovarian failure or uterine disease, and furthermore, relates to the use of a human bone marrow, umbilical cord blood or peripheral blood stem cell composition in the preparation of medicine for treating premature ovarian failure or uterine disease use. Background technique [0002] The ovaries and uterus are important parts of the female reproductive system. The uterus is the organ that produces menstruation and conceives the fetus. It is located in the center of the pelvic cavity, between the bladder and the rectum. The ovaries are a pair of oval reproductive organs located on both sides of the uterus. They are located on the posterolateral side of the fundus of the uterus and meet the side wall of the pelvis. In addition to being fixed to the broad ligament of the uterus by the mesentery, the ovary is also connected to the side wall of the pelvis and the uterus by the sus...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/14A61K35/28A61P15/00A61P15/08
Inventor 唐明淇
Owner 唐明淇
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap